Flu and bacteria: Better prognosis for this potentially fatal combination

April 26, 2013
This shows lung cells infected with influenza virus (stained green) and Legionella (stained red). The nucleus of the cell is stained blue. Copyright: A. Jamieson

Scientists from the Max F. Perutz Laboratories (MFPL) of the University of Vienna and the Medical University of Vienna have provided insights into how much harm bacteria can cause to the lung of people having the flu. An infection with both the flu and bacteria can be a fatal combination. The results could prompt the development of alternative treatments for flu-related bacterial infections, to improve patient outcome and prevent permanent lung damage. The study is published in the renown journal Science.

The flu is caused by an infection with the influenza virus, which mainly attacks the – the nose, throat and bronchi and rarely also the lungs. According to the (WHO), around five to 15 percent of the population are affected by upper during seasonal , and between 250 000-500 000 people die of the illness every year. However, a main cause of death in people having the flu is actually a secondary infection with bacteria.

When we are sick with influenza virus, for many reasons our susceptibility to bacterial infection is increased. One type of bacteria that the immune system usually prevents from spreading and becoming harmful for us is called Legionella pneumophila. However in some circumstances, such as when we're infected with influenza virus, Legionella can cause pneumonia, an inflammatory disease of the lung that if left untreated can leave the lung permanently damaged and even cause death. Amanda Jamieson, the lead author of the report and a research fellow in the Department of Microbiology, Immunobiology and Genetics of the University of Vienna, started to study this phenomenon while working in the laboratory of Ruslan Medzhitov, an at Yale University School of Medicine, USA, and has continued the project in Vienna in collaboration with Dr. Thomas Decker at the MFPL of the University of Vienna and the Medical University of Vienna. "In our model system an infection with influenza and Legionella was fatal. We expected that this would be caused by the bacteria growing and spreading like crazy, but what we actually found was that the number of bacteria didn't change, which was a big surprise", says Amanda Jamieson.

Amanda Jamieson and her collaborators could show now that the damage to the lung tissue caused by a co-infection with flu and Legionella is not properly repaired, as the suppresses the body's ability to repair tissue damage. In case of an additional Legionella infection this may lead to fatal pneumonia. However, treatment with drugs that activate tissue repair pathways significantly improved the outcome. This suggests that new treatment options to deal with co-infections of flu and should be explored. Amanda Jamieson, who will take up an Assistant Professorship at Brown University, USA, in two months, says: "My group will continue to work on tissue repair models and explore different avenues for the treatment of flu/bacterial co-infections."

Explore further: 2009 H1N1 pandemic flu more damaging to lungs, opens opportunities for bacterial infection

More information: Amanda M. Jamieson, Lesley Pasman, Shuang Yu, Pia Gamradt, Robert J. Homer, Thomas Decker and Ruslan Medzhitov: Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science (April 2013).

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

tekram
not rated yet Apr 26, 2013
Re: "treatment with drugs that activate tissue repair pathways significantly improved the outcome" They used AREG.
Amphiregulin, also known as AREG, is a protein that in humans is encoded by the AREG gene. Protein encoded by this gene is a member of the epidermal growth factor family.[1]
It is an autocrine growth factor as well as a mitogen for astrocytes, Schwann cells, fibroblasts and regulatory T-cells [4]. It is related to epidermal growth factor (EGF) and transforming growth factor alpha (TGF-alpha). This protein interacts with the EGF/TGF-alpha receptor to promote the growth of normal epithelial cells and inhibits the growth of certain aggressive carcinoma cell lines (probably via stimulation of T regulatory cells.[4]

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.